C. Michael Gibson

Last updated
C. Michael Gibson
C. Michael Gibson.png
Born
NationalityAmerican
EducationUniversity of Chicago, UofC Pritzker School of Medicine, Brigham and Women's Hospital - Harvard Medical School, Beth Israel Deaconess Medical Center - Harvard Medical School
Occupation(s)Interventional cardiologist, researcher, professor
Years active1993-present
Known forInventing TIMI frame count and TIMI myocardial perfusion grade, PERFUSE, founder of WikiDoc, leader of the Baim Institute (formerly Harvard Clinical Research Institute)
Medical career
FieldInterventional cardiology
Website https://www.wikidoc.org/index.php/User:C_Michael_Gibson

Charles Michael Gibson is an American interventional cardiologist at Beth Israel Deaconess Medical Center, cardiovascular researcher, and professor at Harvard Medical School. [1] He is best known for inventing the TIMI frame count and the TIMI myocardial perfusion grade, measures of coronary blood flow. Also famous as creator of world's largest medical encyclopaedia "The WikiDoc".

Contents

Early life and education

Gibson was born and raised in Tulsa, Oklahoma. He attended the University of Chicago and the University of Chicago Pritzker School of Medicine where he earned his Bachelor of Science, Master of Science, and Doctor of Medicine (MD) degrees in Biology and Medicine. [2] In 1989, Gibson completed his internship and residency in Internal Medicine at Brigham and Women's Hospital at Harvard Medical School. [2] From 1989 to 1993, he was a fellow at Beth Israel Deaconess Medical Center at Harvard Medical School. [2]

Career

Gibson returned in 1992 to Brigham to serve as Chief Medical Resident. He subsequently held positions as Director of the Coronary Care Unit of Beth Israel Deaconess Medical Center, Director of the Cath Lab and Chief of Cardiology at the West Roxbury Veterans Administration Hospital. He served as Cath Lab Director and Associate Chief of Cardiology at University of California, San Francisco before coming back to Boston where he served as Associate Chief of Cardiology of Beth Israel Deaconess Medical Center. [3]

Gibson is the inventor of the TIMI frame count and the TIMI myocardial perfusion grade, measures of coronary blood flow. He also led the first large trial (the PIONEER trial) to show that dual therapy with an antiplatelet and an anticoagulant is superior to triple therapy with two antiplatelet agents in patients with atrial fibrillation who require a stent. He was appointed CEO of the BAIM Institute for Clinical Research, a non-profit academic research organization (ARO) known formerly as Harvard Clinical Research Institute (HCRI). [3] Gibson founded and is Editor-in-Chief of WikiDoc, an online open source encyclopedia of medicine. [4] He was medical lead while partnering with Microsoft, Google, and Yahoo! to design Schema.org, a system of content classification to improve medical search results. [5]

Gibson founded and leads PERFUSE, an academic research organization. [3] He has been principal investigator and/or led core services for 106 clinical trials. Under Gibson, PERFUSE built a master database consisting of TIMI studies spanning 25 years and involving 100,000 patients. [6] He has led phase 1-4 clinical trials and cardiology megatrials exceeding 30,000 patients. [6] Gibson is an at-large member of the US Food and Drug Administration’s cardiorenal panel having served as a standing member from 2017 to 2021.

Recognition

In 2014, Thomson Reuters voted Gibson one of the most influential scientific minds of 2002-2012. [7] He was voted one of Boston's Top Doctors in Boston magazine from 2009 to 2012, [2] one of America’s Top Doctors in U.S. News & World Report from 2010 to 2014, [2] and one of America’s Top Doctors by Castle Connolly Medical in 2012. [8] In a 2021 peer-reviewed article in AIMS Public Health, Gibson was ranked the #1 cardiology influencer on Twitter. [9]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Cardiac stress test</span> Measures the hearts ability to respond to external stress in a controlled clinical environment

A cardiac stress test is a cardiological examination that evaluates the cardiovascular system's response to external stress within a controlled clinical setting. This stress response can be induced through physical exercise or intravenous pharmacological stimulation of heart rate.

<span class="mw-page-title-main">James B. Herrick</span> American physician

James Bryan Herrick was an American physician and professor of medicine who practiced and taught in Chicago. He is credited with the description of sickle-cell disease and was one of the first physicians to describe the symptoms of myocardial infarction.

<span class="mw-page-title-main">Acute coronary syndrome</span> Dysfunction of the heart muscles due to insufficient blood flow

Acute coronary syndrome (ACS) is a syndrome due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies. The most common symptom is centrally located pressure-like chest pain, often radiating to the left shoulder or angle of the jaw, and associated with nausea and sweating. Many people with acute coronary syndromes present with symptoms other than chest pain, particularly women, older people, and people with diabetes mellitus.

<span class="mw-page-title-main">Unstable angina</span> Chest pain due to heart muscles that is easily provoked

Unstable angina is a type of angina pectoris that is irregular or more easily provoked. It is classified as a type of acute coronary syndrome.

<span class="mw-page-title-main">Percutaneous coronary intervention</span> Medical techniques used to manage coronary occlusion

Percutaneous coronary intervention (PCI) is a minimally invasive non-surgical procedure used to treat narrowing of the coronary arteries of the heart found in coronary artery disease. The procedure is used to place and deploy coronary stents, a permanent wire-meshed tube, to open narrowed coronary arteries. PCI is considered 'non-surgical' as it uses a small hole in a peripheral artery (leg/arm) to gain access to the arterial system, an equivalent surgical procedure would involve the opening of the chest wall to gain access to the heart area. The term 'coronary angioplasty with stent' is synonymous with PCI. The procedure visualises the blood vessels via fluoroscopic imaging and contrast dyes. PCI is performed by an interventional cardiologists in a catheterization laboratory setting.

Myocardial stunning or transient post-ischemic myocardial dysfunction is a state of mechanical cardiac dysfunction that can occur in a portion of myocardium without necrosis after a brief interruption in perfusion, despite the timely restoration of normal coronary blood flow. In this situation, even after ischemia has been relieved and myocardial blood flow (MBF) returns to normal, myocardial function is still depressed for a variable period of time, usually days to weeks. This reversible reduction of function of heart contraction after reperfusion is not accounted for by tissue damage or reduced blood flow, but rather, its thought to represent a perfusion-contraction "mismatch". Myocardial stunning was first described in laboratory canine experiments in the 1970s where LV wall abnormalities were observed following coronary artery occlusion and subsequent reperfusion.

<span class="mw-page-title-main">Myocardial perfusion imaging</span> Nuclear medicine imaging method

Myocardial perfusion imaging or scanning is a nuclear medicine procedure that illustrates the function of the heart muscle (myocardium).

Avijit Lahiri is a researcher in cardiology in the UK.

The Thrombolysis In Myocardial Infarction (TIMI) Study Group, is an academic research organization (ARO) affiliated with Brigham and Women's Hospital and Harvard Medical School with a focus in the field of cardiovascular disease. The group has its headquarters in Boston, Massachusetts.

Sean Patrick Pinney is an American cardiologist and the Director of both the Advanced Heart Failure and Cardiac Transplant Program and the Pulmonary Hypertension Program at Mount Sinai Medical Center in New York City.

<span class="mw-page-title-main">Myocardial infarction</span> Interruption of cardiac blood supply

A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops in one of the coronary arteries of the heart, causing infarction to the heart muscle. The most common symptom is retrosternal chest pain or discomfort that classically radiates to the left shoulder, arm, or jaw. The pain may occasionally feel like heartburn.

<span class="mw-page-title-main">Reperfusion therapy</span> Restoring blood flow post-heart attack

Reperfusion therapy is a medical treatment to restore blood flow, either through or around, blocked arteries, typically after a heart attack. Reperfusion therapy includes drugs and surgery. The drugs are thrombolytics and fibrinolytics used in a process called thrombolysis. Surgeries performed may be minimally-invasive endovascular procedures such as a percutaneous coronary intervention (PCI), which involves coronary angioplasty. The angioplasty uses the insertion of a balloon and/or stents to open up the artery. Other surgeries performed are the more invasive bypass surgeries that graft arteries around blockages.

<span class="mw-page-title-main">Electrocardiography in myocardial infarction</span>

Electrocardiography in suspected myocardial infarction has the main purpose of detecting ischemia or acute coronary injury in emergency department populations coming for symptoms of myocardial infarction (MI). Also, it can distinguish clinically different types of myocardial infarction.

<span class="mw-page-title-main">Francis M. Fesmire</span> American emergency physician (1969–2014)

Francis Miller Fesmire was an American emergency physician and a nationally recognized expert in myocardial infarction. He authored numerous academic articles and assisted in the development of clinical guidelines on the standard of care in treating patients with suspected myocardial infarction by the American College of Emergency Physicians and the American Heart Association/American College of Cardiology. He performed numerous research investigations in chest pain patients, reporting the usefulness of continuous 12-lead ECG monitoring, two-hour delta cardiac marker testing, and nuclear cardiac stress testing in the emergency department. The culmination of his studies was The Erlanger Chest Pain Evaluation Protocol published in the Annals of Emergency Medicine in 2002. In 2011 he published a novel Nashville Skyline that received a 5 star review by ForeWord Reviews. His most recent research involved the risk stratification of chest pain patients in the emergency department.

A diagnosis of myocardial infarction is created by integrating the history of the presenting illness and physical examination with electrocardiogram findings and cardiac markers. A coronary angiogram allows visualization of narrowings or obstructions on the heart vessels, and therapeutic measures can follow immediately. At autopsy, a pathologist can diagnose a myocardial infarction based on anatomopathological findings.

<span class="mw-page-title-main">Management of acute coronary syndrome</span>

Management of acute coronary syndrome is targeted against the effects of reduced blood flow to the affected area of the heart muscle, usually because of a blood clot in one of the coronary arteries, the vessels that supply oxygenated blood to the myocardium. This is achieved with urgent hospitalization and medical therapy, including drugs that relieve chest pain and reduce the size of the infarct, and drugs that inhibit clot formation; for a subset of patients invasive measures are also employed. Basic principles of management are the same for all types of acute coronary syndrome. However, some important aspects of treatment depend on the presence or absence of elevation of the ST segment on the electrocardiogram, which classifies cases upon presentation to either ST segment elevation myocardial infarction (STEMI) or non-ST elevation acute coronary syndrome (NST-ACS); the latter includes unstable angina and non-ST elevation myocardial infarction (NSTEMI). Treatment is generally more aggressive for STEMI patients, and reperfusion therapy is more often reserved for them. Long-term therapy is necessary for prevention of recurrent events and complications.

<span class="mw-page-title-main">Cardiac magnetic resonance imaging perfusion</span>

Cardiac magnetic resonance imaging perfusion, also known as stress CMR perfusion, is a clinical magnetic resonance imaging test performed on patients with known or suspected coronary artery disease to determine if there are perfusion defects in the myocardium of the left ventricle that are caused by narrowing of one or more of the coronary arteries.

<span class="mw-page-title-main">Ischemic cardiomyopathy</span> Medical condition

Ischemic cardiomyopathy is a type of cardiomyopathy caused by a narrowing of the coronary arteries which supply blood to the heart. Typically, patients with ischemic cardiomyopathy have a history of acute myocardial infarction, however, it may occur in patients with coronary artery disease, but without a past history of acute myocardial infarction. This cardiomyopathy is one of the leading causes of sudden cardiac death. The adjective ischemic means characteristic of, or accompanied by, ischemia — local anemia due to mechanical obstruction of the blood supply.

Remote ischemic conditioning (RIC) is an experimental medical procedure that aims to reduce the severity of ischaemic injury to an organ such as the heart or the brain, most commonly in the situation of a heart attack or a stroke, or during procedures such as heart surgery when the heart may temporary suffer ischaemia during the operation, by triggering the body's natural protection against tissue injury. Although noted to have some benefits in experimental models in animals, this is still an experimental procedure in humans and initial evidence from small studies have not been replicated in larger clinical trials. Successive clinical trials have failed to identify evidence supporting a protective role in humans.

<span class="mw-page-title-main">John A. Ambrose</span> American physician

John A. Ambrose is an American physician who is an expert in coronary artery disease. He is one of the pioneers in acute coronary syndromes having published over 40 articles in the cardiology literature between 1985 and 2000 on their pathogenesis. He has also published on cigarette smoking and cardiovascular disease. Working with his PhD candidate, Rajat Barua, utilizing a novel in vitro model, they described the effects of cigarette smoking on nitric oxide biosynthesis, endothelial function, and endothelial-derived fibrinolytic and antithrombotic factors. Their 2004 update on cigarette smoking and cardiovascular disease published in the Journal of the American College of Cardiology has been referenced over 2,100 times as of 2020. Ambrose is a Professor of Clinical Medicine at the University of California, San Francisco. He was also a Director of the Cardiac Catheterization Laboratory at Mount Sinai Hospital and received a National Leadership Award from the National Republican Congressional Committee.

References

  1. Malamut, Melissa (2013-04-18). "Ask the Expert: What is Broken Heart Syndrome?". Boston Magazine. Retrieved 2023-03-06.
  2. 1 2 3 4 5 "Dr. C. Michael Gibson, MD". US News & World Report.
  3. 1 2 3 "C. Michael Gibson, MD". BAIM Institute for Clinical Research.
  4. "User:C Michael Gibson - wikidoc". www.wikidoc.org. Retrieved 2023-03-06.
  5. "Schema.org - Schema.org". schema.org. Retrieved 2023-03-06.
  6. 1 2 "C. Michael Gibson, MD, MSCAI | SCAI". scai.org. Retrieved 2023-03-06.
  7. "BIDMC researchers named among 'the most influential scientific minds'". EurekAlert!. Retrieved 2023-03-06.
  8. "The American Registry". www.americanregistry.com. Retrieved 2023-03-06.
  9. Kesiena, Onoriode; Henry K, Onyeaka; Setri, Fugar; Alexis K, Okoh; Annabelle Santos, Volgman (2021-10-26). "The top 100 Twitter influencers in cardiology". AIMS Public Health. 8 (4): 743–753. doi:10.3934/publichealth.2021058. PMC   8568598 . PMID   34786432.